What this means
Peptide-based therapies are increasingly used in urology and sexual medicine, although adoption is often influenced by off-label prescribing, direct-to-consumer promotion, and limited long-term safety data. We review mechanisms, clinical evidence, dosing, safety, and regulatory status of these agents.
A plain-English summary is on its way. Until then, this is the start of the authors' own summary.
- Who it was tested in
- People
- Kind of research
- A summary of earlier studies
The science
- Original title
- Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review.
- Authors
- Vasylieva V, West A, Karpman E
- Journal
- Sexual medicine reviews
- Published
- Oct 12, 2026
- Study type
- Review · in humans
- PMID
- 42862021 ↗
Abstract
Background
Peptide-based therapies are increasingly used in urology and sexual medicine, although adoption is often influenced by off-label prescribing, direct-to-consumer promotion, and limited long-term safety data. We review mechanisms, clinical evidence, dosing, safety, and regulatory status of these agents.
What they did
A structured search of PubMed, Scopus, and Google Scholar identified studies of peptide-based therapies in sexual medicine. Search terms included Bremelanotide, Melanotan II, Kisspeptin, Oxytocin, PnPP-19, Gonadorelin and growth hormone secretagogues, including GHRP-2, GHRP-6, Ibutamoren, Ipamorelin, Tesamorelin, Sermorelin, and CJC-1295. Of 725 records, 76 studies met inclusion criteria. Findings were synthesized narratively given heterogeneity across studies.
What they found
Peptides reviewed act through diverse mechanisms, including central modulation of desire and arousal, stimulation of the hypothalamic-pituitary-gonadal and growth hormone axes, and nitric oxide-mediated effects on erectile physiology. Bremelanotide and Tesamorelin are the most clinically established agents, with defined dosing and regulatory approval for selected indications. Kisspeptin shows early promise but remains investigational. Growth hormone secretagogues reliably increase growth hormone and insulin-like growth factor 1 concentrations; however, evidence for improved sexual function, physical performance, or quality of life remains limited. Melanotan II, Ibutamoren, CJC-1295, and related agents remain accessible through unregulated markets, raising concerns about product quality, dosing variability, and incompletely characterized adverse effects. Oxytocin has biologic plausibility but limited efficacy data, whereas PnPP-19 remains preclinical. Gonadorelin was Food and Drug Administration approved but is no longer manufactured. Across peptide classes, safety data are limited by short follow-up, small samples, and incomplete assessment of cardiovascular, metabolic, and oncologic outcomes. Peptide-based therapies in urology and sexual medicine show selective therapeutic potential, but most remain insufficiently validated for clinical use. Clinicians should distinguish approved therapies from investigational and nonregulated compounds and counsel patients regarding uncertain benefit, potential harm, and risks of unsupervised use. Randomized trials with standardized dosing and long-term safety assessment are needed before broader adoption.
The authors' abstract, grouped under plain headings from its own section labels.
Vasylieva V, West A, Karpman E Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. Sexual medicine reviews. 2026. doi:10.1093/sxmrev/qeag078. PMID: 42862021. https://pubmed.ncbi.nlm.nih.gov/42862021/
Related research
Tesamorelin reduced belly fat in people with HIV and fat changes
Four trials with 909 people found tesamorelin lowered belly fat and waist size. Long-term safety and how long the benefit lasts are still unclear.
Anterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report.
BACKGROUND: Anterior cervical osteophytes can compress the esophagus, producing dysphagia.
Study plan tests a drug plus exercise for physical strength in older adults with HIV
This paper describes the plan for a trial, not its results. It does not yet tell us whether the drug and exercise help.
The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.
Cognitive decline with age and other clinical conditions are linked with reduced hypothalamic-pituitary-adrenal (HPA) axis function.
See all research on Tesamorelin →